The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letters to the EditorFull Access

Elevating the Role of Subjective Experience in the Clinic: Response to Fanselow and Pennington

To the Editor: It is widely accepted that threat exposure activates the amygdala and elicits behavioral defense reactions, physiological responses, and subjective states of fear in humans. Our central thesis is that the changes in behavior and physiology can be dissociated from the changes in subjective state, with the former depending on the amygdala but the latter depending more heavily on cortical areas. We are pleased to address criticisms of this central idea from Fanselow and Pennington.

Fanselow and Pennington cite evidence that patients with amygdala lesions have both reduced subjective experiences and behavioral and physiological responses to threatening stimuli. However, the same group they referenced later reported opposite findings (1), as did Anderson and Phelps (2). The latter findings are consistent with results from studies using subliminal stimulation in healthy humans and studies of humans with “blindsight.” Both sets of studies show that threats that are not consciously reportable and that fail to elicit conscious fear nevertheless elicit amygdala activity and physiological responses (3).

In contrast to Fanselow and Pennington’s suggestion, we do think that the study of behavioral and physiological defense responses inform understanding of subjective states. Even though these phenomena are clearly dissociable, changing behavior and physiology can indirectly modulate the subjective states of fear and anxiety because the circuits for these phenomena, though distinct, interact.

Noting that threat exposure leads patients with anxiety disorders to manifest changes in both subjective fear and behavioral physiology, Fanselow and Pennington argue that clinical data contradict our framework. They also note that subjective ratings of fear across the acquisition, extinction, and re-emergence of a fear memory, and subjective trait-like assessments of anxiety, are correlated with autonomic responses. However, contrary to their assertions, a wealth of findings show that subjective reports of fear are poorly correlated with measures of behavior and physiology (49). Further, recent studies using a novel, sophisticated approach to brain imaging show successful threat extinction in the absence of the arousal of conscious fear (10).

Fanselow and Pennington argue that physiological and behavioral measures predict the efficacy of both behavioral and pharmacological interventions. This claim not only contradicts our views but also the views of other researchers. For example, Griebel and Holmes (11) summarized the state of efforts to use neuroscience research to develop novel anxiolytic medications and to predict efficacy. In their words, this work has been “disappointing” because rodent research findings have rarely translated into effective treatments for problems related to fear and anxiety. A similar conclusion was reached by pharmaceutical scientists who found that the rodent model did not lead to new treatments (12).

Fanselow and Pennington also suggest that our framework forces insights into the neurobiology of fear gained from animal studies to be lost. In our view, data from animals are important for clinical understanding, especially when their interpretation is restricted to behavioral and physiological responses that can be similarly measured in humans and animals. Adopting this approach would foster more realistic expectations for the translation of basic science work into therapies for anxiety disorders.

Fanselow and Pennington suggest that the unreliability and semiquantitative nature of subjective report led to a shift away from its use. Clearly, subjective reports have limitations (e.g., as an index of motivations underlying behavior or as a fully accurate index of past experiences). However, they have unique strengths, which make them an important indicator of people’s immediate experiences (13, 14). Moreover, they are at least as reliable as physiological responses to threats (15). Because of these features, neuroscience is not shifting away from subjective reports; rather, research on consciousness is thriving (16, 17), and subjective report is the gold standard in this field. As a state of consciousness, subjective fear can be explored using subjective report as well as novel quantitative assessment methods (1820).

Finally, Fanselow and Pennington suggest that an emphasis on subjective experience and self-report turns psychiatry in the direction of a “bleak past.” But leading anxiety researchers argue that self-report generates “valid measures of key constructs, some of which cannot be measured in any other way” and that self-report is “sometimes the best measure of the construct of interest” (21). We agree and hold that failure to acknowledge the subjective state as an important, independent area of scientific inquiry ignores vital aspects of patients’ clinical experiences. Moreover, focusing on the subjective state frees psychiatry from the bleak legacy of behaviorism and reductionism. At the same time, it elevates patients’ experiences to a legitimate focus of both treatment and neuroscience research on novel therapeutics.

From the Section on Development and Affective Neuroscience, NIMH Intramural Research Program, Bethesda, Md.; the Center for Neural Science, the Department of Psychology, the Department of Psychiatry, and the Department of Child and Adolescent Psychiatry, New York University, New York; and the Nathan Kline Institute, Orangeburg, N.Y.
Address correspondence to Dr. LeDoux ().

The authors’ disclosures accompany the original article.

References

1 Feinstein JS, Buzza C, Hurlemann R, et al.: Fear and panic in humans with bilateral amygdala damage. Nat Neurosci 2013; 16:270–272Crossref, MedlineGoogle Scholar

2 Anderson AK, Phelps EA: Is the human amygdala critical for the subjective experience of emotion? Evidence of intact dispositional affect in patients with amygdala lesions. J Cogn Neurosci 2002; 14:709–720Crossref, MedlineGoogle Scholar

3 LeDoux JE: Anxious: Using the Brain to Understand and Treat Fear and Anxiety. New York, Viking-Penguin Random House, 2015Google Scholar

4 Lang PJ: Fear reduction and fear behavior: problems in treating a construct, in Research in Psychotherapy. Edited by Schlien JM. Washington, DC, American Psychological Association, 1968, pp 90–103CrossrefGoogle Scholar

5 Rachman S: Anxiety, 2nd ed. Hove, East Sussex, England, Psychology Press, 2004Google Scholar

6 Hugdahl K: The three-systems-model of fear and emotion: a critical examination. Behav Res Ther 1981; 19:75–85Crossref, MedlineGoogle Scholar

7 Zinbarg RE: Concordance and synchrony in measures of anxiety and panic reconsidered: a hierarchical model of anxiety and panic. Behav Ther 1998; 29:301–323CrossrefGoogle Scholar

8 Grey S, Sartory G, Rachman S: Synchronous and desynchronous changes during fear reduction. Behav Res Ther 1979; 17:137–147Crossref, MedlineGoogle Scholar

9 Hodgson R, Rachman S: II. Desynchrony in measures of fear. Behav Res Ther 1974; 12:319–326Crossref, MedlineGoogle Scholar

10 Koizumi A, Amano K, Cortese A, et al.: Fear reduction without fear through reinforcement of neural activity that bypasses conscious exposure (letter). Nat Hum Behav 2016; 1:0006Crossref, MedlineGoogle Scholar

11 Griebel G, Holmes A: 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov 2013; 12:667–687Crossref, MedlineGoogle Scholar

12 Miller G: Is pharma running out of brainy ideas? Science 2010; 329:502–504Crossref, MedlineGoogle Scholar

13 Ericcson KA, Simon H: Protocol Analysis: Verbal Reports as Data. Cambridge, Mass, MIT Press, 1993Google Scholar

14 Wilson TD: The proper protocol: validity and completeness of verbal reports. Psychol Sci 1994; 5:249–252CrossrefGoogle Scholar

15 Shechner T, Britton JC, Ronkin EG, et al.: Fear conditioning and extinction in anxious and nonanxious youth and adults: examining a novel developmentally appropriate fear-conditioning task. Depress Anxiety 2015; 32:277–288Crossref, MedlineGoogle Scholar

16 Dehaene S: Consciousness and the Brain: Deciphering How the Brain Codes Our Thoughts. New York, Penguin, 2014Google Scholar

17 Lau H, Rosenthal D: Empirical support for higher-order theories of conscious awareness. Trends Cogn Sci 2011; 15:365–373Crossref, MedlineGoogle Scholar

18 Overgaard M, Sandberg K: Kinds of access: different methods for report reveal different kinds of metacognitive access, in The Cognitive Neuroscience of Metacognition. Edited by Fleming SM, Frith CD. Berlin; Heidelberg, Germany, Springer-Verlag, 2014, pp 67–86CrossrefGoogle Scholar

19 Maniscalco B, Lau H: The signal processing architecture underlying subjective reports of sensory awareness. Neurosci Conscious 2016; 1:niw002Google Scholar

20 LeDoux JE, Brown R: A higher-order theory of emotional consciousness. Proc Natl Acad Sci USA 2017; 114:E2016–E2025Crossref, MedlineGoogle Scholar

21 Zoellner LA, Foa EB: Applying Research Domain Criteria (RDoC) to the study of fear and anxiety: a critical comment. Psychophysiology 2016; 53:332–335Crossref, MedlineGoogle Scholar